Literature DB >> 17383182

Impact on oxidative phosphorylation of immortalization with the telomerase gene.

K Auré1, K Mamchaoui, P Frachon, G S Butler-Browne, A Lombès, V Mouly.   

Abstract

Skin fibroblasts are essential tools for biochemical, genetic and physiopathological investigations of mitochondrial diseases. Their immortalization has been previously performed to overcome the limited number of divisions of these primary cells but it has never been systematically evaluated with respect to efficacy and impact on the oxidative phosphorylation (OXPHOS) characteristics of the cells. We successfully immortalized with the human telomerase gene 15 human fibroblasts populations, 4 derived from controls and 11 from patients with diverse respiratory chain defects. Immortalization induced significant but mild modification of the OXPHOS characteristics of the cells with lower rates of oxygen consumption and ATP synthesis associated with their loose coupling. However, it never significantly altered the type and severity of any genetic OXPHOS defect present prior to immortalization. Furthermore, it did not significantly modify the cells' dependence on glucose and sensitivity to galactose thus showing that immortalized cells could be screened by their nutritional requirement. Immortalized skin fibroblasts with significant OXPHOS defect provide reliable tools for the diagnosis and research of the genetic cause of mitochondrial defects. They also represent precious material to investigate the cellular responses to these defects, even though these should afterwards be verified in unmodified primary cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17383182     DOI: 10.1016/j.nmd.2007.01.019

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  12 in total

1.  Severe respiratory complex III defect prevents liver adaptation to prolonged fasting.

Authors:  Laura S Kremer; Caroline L'hermitte-Stead; Pierre Lesimple; Mylène Gilleron; Sandrine Filaut; Claude Jardel; Tobias B Haack; Tim M Strom; Thomas Meitinger; Hatem Azzouz; Neji Tebib; Hélène Ogier de Baulny; Guy Touati; Holger Prokisch; Anne Lombès
Journal:  J Hepatol       Date:  2016-05-02       Impact factor: 25.083

2.  A yeast-based assay identifies drugs active against human mitochondrial disorders.

Authors:  Elodie Couplan; Raeka S Aiyar; Roza Kucharczyk; Anna Kabala; Nahia Ezkurdia; Julien Gagneur; Robert P St Onge; Bénédicte Salin; Flavie Soubigou; Marie Le Cann; Lars M Steinmetz; Jean-Paul di Rago; Marc Blondel
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-29       Impact factor: 11.205

3.  Homoplasmic mitochondrial tRNAPro mutation causing exercise-induced muscle swelling and fatigue.

Authors:  Karine Auré; Guillemette Fayet; Ivan Chicherin; Benoit Rucheton; Sandrine Filaut; Anne-Marie Heckel; Julie Eichler; Florence Caillon; Yann Péréon; Nina Entelis; Ivan Tarassov; Anne Lombès
Journal:  Neurol Genet       Date:  2020-07-15

4.  Laminopathies disrupt epigenomic developmental programs and cell fate.

Authors:  Jelena Perovanovic; Stefania Dell'Orso; Viola F Gnochi; Jyoti K Jaiswal; Vittorio Sartorelli; Corinne Vigouroux; Kamel Mamchaoui; Vincent Mouly; Gisèle Bonne; Eric P Hoffman
Journal:  Sci Transl Med       Date:  2016-04-20       Impact factor: 17.956

5.  Mitochondrial vulnerability and increased susceptibility to nutrient-induced cytotoxicity in fibroblasts from leigh syndrome French canadian patients.

Authors:  Yan Burelle; Chantal Bemeur; Marie-Eve Rivard; Julie Thompson Legault; Gabrielle Boucher; Charles Morin; Lise Coderre; Christine Des Rosiers
Journal:  PLoS One       Date:  2015-04-02       Impact factor: 3.240

6.  Upregulation of Mitochondrial Content in Cytochrome c Oxidase Deficient Fibroblasts.

Authors:  Aviram Kogot-Levin; Ann Saada; Gil Leibowitz; Devorah Soiferman; Liza Douiev; Itamar Raz; Sarah Weksler-Zangen
Journal:  PLoS One       Date:  2016-10-25       Impact factor: 3.240

7.  Allele-Specific CRISPR/Cas9 Correction of a Heterozygous DNM2 Mutation Rescues Centronuclear Myopathy Cell Phenotypes.

Authors:  Aymen Rabai; Léa Reisser; Bernardo Reina-San-Martin; Kamel Mamchaoui; Belinda S Cowling; Anne-Sophie Nicot; Jocelyn Laporte
Journal:  Mol Ther Nucleic Acids       Date:  2019-02-27

8.  Lamin-Related Congenital Muscular Dystrophy Alters Mechanical Signaling and Skeletal Muscle Growth.

Authors:  Daniel J Owens; Julien Messéant; Sophie Moog; Mark Viggars; Arnaud Ferry; Kamel Mamchaoui; Emmanuelle Lacène; Norma Roméro; Astrid Brull; Gisèle Bonne; Gillian Butler-Browne; Catherine Coirault
Journal:  Int J Mol Sci       Date:  2020-12-30       Impact factor: 5.923

9.  Allele-specific silencing therapy for Dynamin 2-related dominant centronuclear myopathy.

Authors:  Delphine Trochet; Bernard Prudhon; Maud Beuvin; Cécile Peccate; Stéphanie Lorain; Laura Julien; Sofia Benkhelifa-Ziyyat; Aymen Rabai; Kamel Mamchaoui; Arnaud Ferry; Jocelyn Laporte; Pascale Guicheney; Stéphane Vassilopoulos; Marc Bitoun
Journal:  EMBO Mol Med       Date:  2018-02       Impact factor: 12.137

10.  Lamin Mutations Cause Increased YAP Nuclear Entry in Muscle Stem Cells.

Authors:  Daniel J Owens; Martina Fischer; Saline Jabre; Sophie Moog; Kamel Mamchaoui; Gillian Butler-Browne; Catherine Coirault
Journal:  Cells       Date:  2020-03-27       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.